Caris Life Sciences (NASDAQ:CAI) Director Buys $501,457.50 in Stock

Caris Life Sciences, Inc. (NASDAQ:CAI) Director Jeff Vacirca acquired 31,050 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $16.15 per share, with a total value of $501,457.50. Following the acquisition, the director owned 49,671 shares in the company, valued at $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Caris Life Sciences Stock Up 3.8%

Shares of NASDAQ:CAI opened at $15.25 on Friday. Caris Life Sciences, Inc. has a 52-week low of $14.19 and a 52-week high of $42.50. The business has a 50 day moving average price of $18.77. The company has a market capitalization of $4.31 billion and a PE ratio of -2.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 7.35 and a current ratio of 7.05.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 98.28%. The firm had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. During the same period in the previous year, the business posted ($1.73) earnings per share. Caris Life Sciences’s quarterly revenue was up 125.4% on a year-over-year basis. On average, sell-side analysts anticipate that Caris Life Sciences, Inc. will post 0.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CAI has been the subject of a number of research analyst reports. Weiss Ratings upgraded Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Canaccord Genuity Group cut their price target on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. BTIG Research lowered their price objective on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, May 8th. New Street Research assumed coverage on Caris Life Sciences in a research report on Friday, May 8th. They set a “market perform” rating on the stock. Finally, Piper Sandler assumed coverage on Caris Life Sciences in a report on Friday, April 10th. They set a “neutral” rating and a $21.00 price target for the company. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Caris Life Sciences has a consensus rating of “Moderate Buy” and an average target price of $27.56.

Hedge Funds Weigh In On Caris Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. raised its stake in shares of Caris Life Sciences by 14.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after purchasing an additional 1,180,200 shares in the last quarter. Braidwell LP lifted its stake in Caris Life Sciences by 6.8% during the fourth quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after purchasing an additional 500,000 shares during the last quarter. PointState Capital LP grew its holdings in shares of Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock worth $181,271,000 after acquiring an additional 2,834,986 shares during the last quarter. Orbimed Advisors LLC raised its holdings in Caris Life Sciences by 2.7% during the 4th quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock worth $84,070,000 after buying an additional 81,153 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Caris Life Sciences by 185.0% during the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after purchasing an additional 1,587,176 shares during the period.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.